Patents by Inventor Tenekua TAPIA
Tenekua TAPIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9541545Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: June 3, 2014Date of Patent: January 10, 2017Assignee: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Publication number: 20150111766Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Anatoly KACHURIN, Olga KACHURINA, Vaughan WITTMAN, Tenekua TAPIA
-
Patent number: 8962256Abstract: Hemagglutination (HA) and hemagglutination inhibition (HAI) functional assays remain important instruments of analysis of virus-cell interaction and protecting efficacy of virus-specific antibodies and sera. However, they demonstrate limited sensitivity towards many viruses, and require significant volumes of viruses, erythrocytes, sera, and antibodies. The present invention comprises new and significantly more sensitive versions of the HA and HAI assays based on observing agglutination on activated surfaces of specifically opsonized plates and ELISA plates rather than in solution. A version of the new assay that uses ELISA plates additionally allows characterizing the affinity of functional antibodies in the tested sera and fluids, which is not possible in the classical HAI assay. The methods of the present invention can also be used to improve the sensitivity of agglutination methods based on latex beads and to develop agglutination methods using target cells other than erythrocytes.Type: GrantFiled: October 20, 2010Date of Patent: February 24, 2015Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Anatoly Kachurin, Vaughan Wittman, Mike N. Nguyen, Olga Kachurina, Tenekua Tapia, Vipra Dhir, Alexander Karol
-
Patent number: 8778347Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: GrantFiled: November 11, 2009Date of Patent: July 15, 2014Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
-
Publication number: 20110097705Abstract: Hemagglutination (HA) and hemagglutination inhibition (HAI) functional assays remain important instruments of analysis of virus-cell interaction and protecting efficacy of virus-specific antibodies and sera. However, they demonstrate limited sensitivity towards many viruses, and require significant volumes of viruses, erythrocytes, sera, and antibodies. The present invention comprises new and significantly more sensitive versions of the HA and HAI assays based on observing agglutination on activated surfaces of specifically opsonized plates and ELISA plates rather than in solution. A version of the new assay that uses ELISA plates additionally allows characterizing the affinity of functional antibodies in the tested sera and fluids, which is not possible in the classical HAI assay. The methods of the present invention can also be used to improve the sensitivity of agglutination methods based on latex beads and to develop agglutination methods using target cells other than erythrocytes.Type: ApplicationFiled: October 20, 2010Publication date: April 28, 2011Applicant: VAXDESIGN CORP.Inventors: Anatoly Kachurin, Vaughan Wittman, Mike N. Nguyen, Olga Kachurina, Tenekua Tapia, Vipra Dhir, Alexander Karol
-
Publication number: 20100120020Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.Type: ApplicationFiled: November 11, 2009Publication date: May 13, 2010Applicant: VaxDesign Corp.Inventors: Anatoly KACHURIN, Olga KACHURINA, Vaughan WITTMAN, Tenekua TAPIA
-
Publication number: 20090325148Abstract: Hemagglutination assays and hemagglutination inhibition assays were introduced in medical and virology practice more than 60 years ago. Since then, these assays have become important tools for measuring concentrations and strengths of viral cultures, the efficacy of the anti-viral immunization, and for studying the neutralizing capacity of virus-specific antibodies. The present invention comprises an improved hemagglutination inhibition assay (HAI), with at least about a 10-fold increase in sensitivity versus the traditional the HAI, to provide more accurate measurements of components in, for example, fluids from the in vitro MIMICĀ® system when assessing the effects of anti-viral vaccines (e.g., for seasonal influenza).Type: ApplicationFiled: June 30, 2009Publication date: December 31, 2009Inventors: Anatoly KACHURIN, Vaughan WITTMAN, Olga KACHURINA, Tenekua TAPIA